Want to see SNTI full AI Analyst Report?
SNTI Stock Chart & Stats
$0.40
>-$0.01(-0.97%)
At close: 4:00 PM EDT
$0.40
>-$0.01(-0.97%)
Day’s Range― - ―
52-Week Range$0.34 - $2.88
Previous CloseN/A
Volume63.62K
Average Volume (3M)299.89K
Market Cap
$10.81M
Enterprise Value$35.20M
Total Cash (Recent Filing)$8.94M
Total Debt (Recent Filing)$19.14M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding31,144,754
10 Day Avg. Volume584,382
30 Day Avg. Volume299,887
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap3.26
Enterprise Value/Revenue926.40
Enterprise Value/Gross Profit-10.88
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$12.00Price Target Upside2900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$38.67K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress For SENTI-202FDA feedback that supports a single-arm, multi-center pivotal registration path, plus RMAT and Orphan Drug designations, materially clarifies development strategy. This reduces uncertainty on trial design and time-to-registration, improving the likelihood of achieving value-driving clinical milestones and partner interest over the next 2–6 months.
Synthetic Biology Platform & First-in-class PotentialA differentiated synthetic-biology platform that engineers sensing and control circuits in therapeutic cells creates a durable technological moat. First-in-class off-the-shelf CAR-NK positioning addresses unmet needs in hematologic malignancies and supports multiple program opportunities and licensing or partnership value beyond a single asset.
Secured Financing And Cost Actions Extending RunwayCommitting up to $40M in convertible financing and realizing a $6.9M lease gain materially extended near-term runway and funded CMC/clinical activities. That structural cash support lowers immediate liquidity stress and permits execution of pivotal planning and manufacturing de-risking necessary to reach regulatory inflection points.
Bears Say
Negligible Revenue And Large Recurring LossesWith effectively no product revenue and persistently large losses, the company remains dependent on external financing for operations. Persistent negative operating and free cash flow reduce the firm’s resilience to setbacks and increase the need for dilutive or restrictive financing over the medium term, stressing long-term sustainability.
Deteriorated Balance Sheet And High LeverageCapitalization has weakened markedly: very low equity relative to debt and a large contraction in assets limits financial flexibility. High leverage and a thin equity cushion reduce ability to absorb clinical setbacks, constrain strategic options, and increase creditor influence over operations and future financings.
Aggressive Convertible Note Terms Increase Dilution/repayment RiskFinancing terms (short maturity, extreme cash-pay provisions, full-ratchet anti-dilution and asset-securing liens) create structural downside: if conversion doesn't occur, the repayment burden is large or will force dilutive equity issuance. These terms amplify dilution risk and constrain strategic and financing flexibility.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences, Inc.’s price range in the past 12 months?
Senti Biosciences, Inc. lowest stock price was $0.34 and its highest was $2.88 in the past 12 months.
What is Senti Biosciences, Inc.’s market cap?
Senti Biosciences, Inc.’s market cap is $10.81M.
When is Senti Biosciences, Inc.’s upcoming earnings report date?
Senti Biosciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 18 days.
How were Senti Biosciences, Inc.’s earnings last quarter?
Senti Biosciences, Inc. released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.14.
Is Senti Biosciences, Inc. overvalued?
According to Wall Street analysts Senti Biosciences, Inc.’s price is currently Undervalued.
Does Senti Biosciences, Inc. pay dividends?
Senti Biosciences, Inc. does not currently pay dividends.
What is Senti Biosciences, Inc.’s EPS estimate?
Senti Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences, Inc. have?
Senti Biosciences, Inc. has 31,144,754 shares outstanding.
What happened to Senti Biosciences, Inc.’s price movement after its last earnings report?
Senti Biosciences, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.996%.
Which hedge fund is a major shareholder of Senti Biosciences, Inc.?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senti Biosciences, Inc.
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
SNTI Stock 12 Month Forecast
Average Price Target
$12.00
▲(2900.00% Upside)
Technical Analysis
Plus Therapeutics
―
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
―
Ownership Overview
2.63% Insiders
0.46% Mutual Funds
― Other Institutional Investors
95.18% Public Companies and
Individual Investors